{"pmid":32499636,"title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage.","text":["COVID-19 vaccines: neutralizing antibodies and the alum advantage.","Nat Rev Immunol","Hotez, Peter J","Corry, David B","Strych, Ulrich","Bottazzi, Maria Elena","32499636"],"journal":"Nat Rev Immunol","authors":["Hotez, Peter J","Corry, David B","Strych, Ulrich","Bottazzi, Maria Elena"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32499636","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1038/s41577-020-0358-6","topics":["Treatment"],"weight":1,"_version_":1668804508773253120,"score":9.490897,"similar":[{"pmid":32449171,"title":"COVID-19: are neutralizing antibodies neutralizing enough?","text":["COVID-19: are neutralizing antibodies neutralizing enough?","Transfusion","Kadkhoda, Kamran","32449171"],"journal":"Transfusion","authors":["Kadkhoda, Kamran"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449171","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/trf.15897","keywords":["covid-19","convalescent plasma","sars-cov-2","treatment"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667785213996957696,"score":51.756165},{"pmid":32249063,"pmcid":"PMC7129017","title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.","text":["Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.","Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.","Trends Immunol","Jiang, Shibo","Hillyer, Christopher","Du, Lanying","32249063"],"abstract":["Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs."],"journal":"Trends Immunol","authors":["Jiang, Shibo","Hillyer, Christopher","Du, Lanying"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249063","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.it.2020.03.007","keywords":["mers-cov","sars-cov","sars-cov-2","human coronaviruses","neutralizing antibodies"],"link_erratum_in":"32362491","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490933346306,"score":40.864212}]}